# Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF

> **NCT02387229** · PHASE3 · TERMINATED · sponsor: **Montreal Heart Institute** · enrollment: 1238 (actual)

## Conditions studied

- ATRIAL FIBRILLATION

## Interventions

- **DRUG:** Rivaroxaban
- **OTHER:** standard of care

## Key facts

- **NCT ID:** NCT02387229
- **Lead sponsor:** Montreal Heart Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-03
- **Primary completion:** 2024-05-18
- **Final completion:** 2024-05-18
- **Target enrollment:** 1238 (ACTUAL)
- **Why stopped:** Consensus BRAIN-AF Executive Steering Committee to terminate.
- **Last updated:** 2025-06-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02387229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02387229, "Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02387229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*